
IN RE: RISPERDAL® LITIGATION

Timothy Stange,

Plaintiff,

v.

Janssen Pharmaceuticals, Inc., et al.

Defendants

:
: **PHILADELPHIA COUNTY**
: **COURT OF COMMON PLEAS**
: **TRIAL DIVISION**

: **APRIL TERM 2013**

: **No. 1984**
: **Control No. 18053832**


DOCKETED
SEP 11 2018
NEW JERSEY
COURT

ORDER

AND NOW this 14th day of September, 2018, upon consideration of the Motion for Partial Summary Judgment filed by Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, and Janssen Research & Development, LLC, and any response thereto, it is hereby **ORDERED** and **DECREED** said Motion is **DENIED** and the issue of punitive damages shall be determined under Wisconsin law.

The parties shall be prepared to discuss the issue of trial scheduling at the next Case Management Conference.

BY THE COURT:



ARNOLD L. NEW, J.

Stange Vs Janssen Pharm-ORDER



13040198400317